AI
Abbott has received clearance from the FDA for its imaging software that uses artificial intelligence to provide doctors a better view of blood flow and blockages in heart vessels.
AI algorithms will inform treatment decisions by recognising patterns of data from past treatments.
This marks the fourth clearance for Volpara’s breast health platform since its original authorization back in 2010.
The companies will combine their complementary pathology tools to leverage services for tech-enabled diagnostics, drug discovery and patient care.
The new capital boosts Olive’s valuation to $4 billion.
Valo’s flagship product is its Opal Computational Platform, designed to create a new model for drug discovery.
The startup's technology is now incorporated into Fujifilm's digital x-ray system, in addition to being used in Malaysian clinics.
The company has developed a line of products targeting the mammography space to enable early and accurate breast cancer detection.
Viome has adapted its technology to search for the presence of oral squamous cell carcinoma and oropharyngeal cancer in users’ saliva samples.
Alife also added Deena Shakir, a partner at Lux Capital, to its board of directors.